Wall Street analysts project Procter & Gamble (PG) to report Q4 EPS of $1.43, up 2.1% year-over-year, on revenues of $20.82 billion, a 1.4% increase. However, the consensus EPS estimate has seen a 0.1% downward revision over the past 30 days. While most segments anticipate modest sales growth, analysts forecast a notable slowdown in organic sales growth for key categories like Beauty (1.8% vs 3.0% prior year), Grooming (3.2% vs 7.0% prior year), and Health Care (3.2% vs 4.0% prior year), alongside a projected 7.9% decline in Corporate segment sales, suggesting underlying pressures despite headline growth.
Procter & Gamble is poised for modest top-line and bottom-line growth in its upcoming Q4 report, with analysts forecasting a 2.1% year-over-year increase in EPS to $1.43 and a 1.4% rise in revenue to $20.82 billion. However, this outlook is tempered by a slight 0.1% downward revision in the consensus EPS estimate over the past 30 days and the stock's recent 0.4% decline, which significantly trails the S&P 500's 5.7% gain. A deeper look at segment-level expectations reveals a key concern: a notable deceleration in organic sales growth. Analysts project organic growth to slow to 1.8% in Beauty (from 3.0% in the prior-year quarter), 3.2% in Grooming (from 7.0%), and 3.2% in Health Care (from 4.0%). This suggests waning momentum in core categories, with the Baby, Feminine & Family Care segment expected to be nearly flat with just 0.1% net sales growth. While estimated earnings before income taxes show healthy expansion in Beauty and Grooming, this profitability appears to be driven more by margin improvement than by robust sales growth, a dynamic that may face pressure if top-line trends continue to soften.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
